Tumor invasion after treatment of glioblastoma with bevacizumab: Radiographic and pathologic correlation in humans and mice

Neuro-Oncology

Volumn 12, Issue 3, 2010, Pages 233-242

  De Groot, John F ^a   Fuller, Gregory ^a   Kumar, Ashok J ^a   Piao, Yuji ^a   Eterovic, Karina ^a   Ji, Yongjie ^a   Conrad, Charles A ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Bevacizumab; Glioblastoma; Invasion; Matrix metalloproteinases; VEGF

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; IMMUNOGLOBULIN G; IRINOTECAN; MATRIX METALLOPROTEINASE; SOMATOMEDIN BINDING PROTEIN 2; TEMOZOLOMIDE; VASCULOTROPIN; ANTINEOPLASTIC AGENT; GELATINASE A; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CANCER INVASION; GENE EXPRESSION; GLIOBLASTOMA; HUMAN; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHENOTYPE; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE; ANIMAL; BIOSYNTHESIS; BRAIN TUMOR; CASE REPORT; DRUG SCREENING; IMAGE ENHANCEMENT; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; TUMOR RECURRENCE;

ADULT; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; GLIOBLASTOMA; HUMANS; IMAGE ENHANCEMENT; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; MAGNETIC RESONANCE IMAGING; MALE; MATRIX METALLOPROTEINASE 2; MICE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; XENOGRAFT MODEL ANTITUMOR ASSAYS; YOUNG ADULT;

EID: 77952309402     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nop027     Document Type: Article

References (33)

1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352:987-996. (Pubitemid 40349501)
2. Wong ET, Hess KR, Gleason MJ, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol. 1999; 17:2572-2578.
3. Curran WJ, Jr, Scott CB, Horton J, et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst. 1993; 85:704-710. (Pubitemid 23133591)
4. Millauer B, Shawver LK, Plate KH, Risau W, Ullrich A. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature. 1994; 367:576-579.
5. Folkman J. Tumor angiogenesis. Adv Cancer Res. 1985; 43:175-203.
6. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995; 1:27-31.
7. Parangi S, O'Reilly M, Christofori G, et al. Antiangiogenic therapy of transgenic miceimpairs de novo tumor growth. Proc Natl Acad Sci USA. 1996; 93:2002-2007. (Pubitemid 26079871)
8. Stark-Vance V. Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma [abstract]. Proceedings of the World Federation of Neuro-Oncology Meeting. Neuro-Oncology. 2005; 7:369.
9. Vredenburgh JJ, Desjardins A, Herndon JE, 2nd, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res. 2007; 13:1253-1259. (Pubitemid 46424067)
10. Wagner SA, Desjardins A, Reardon DA, et al. Update on survival from the original phase II trial of bevacizumab and irinotecan in recurrent malignant gliomas [abstract]. J Clin Oncol. 2008; 26abstract 2021.
11. Batchelor TT, Sorensen AG, di Tomaso E, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell. 2007; 11:83-95. (Pubitemid 46075199)
12. Cloughesy TF, Prados MD, Wen PY, et al. A phase II, randomized, noncomparative clinical trial of the effect of bevacizumab (BV) alone orin combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM) [abstract]. J Clin Oncol. 2008;26:abstract 2010b.
13. Norden AD, Young GS, Setayesh K, et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology. 2008; 70:779-787.
14. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005; 307:58-62.
15. Willett CG, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effectsin human rectal cancer. Nat Med. 2004; 10:145-147. (Pubitemid 38524883)
16. Winkler F, Kozin SV, Tong RT, et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell. 2004; 6:553-563. (Pubitemid 40017699)
17. Desjardins A, Barboriak DP, Herndon JE, II, et al. Effect of bevacizumab (BEV) and irinotecan (CPT-11) on dynamic contrast-enhanced magnetic resonanceimaging (DCE-MRI) in glioblastoma (GBM) patients [abstract]. J Clin Oncol. 2008; 26:abstract 2026.
18. Macdonald DR, Cascino TL, Schold SC, Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990; 8:1277-1280.
19. Lal S, Lacroix M, Tofilon P, Fuller GN, Sawaya R, Lang FF. An implantable guide-screw system for brain tumor studies in small animals. J Neurosurg. 2000; 92:326-333. (Pubitemid 30071053)
20. Wang H, Wang H, Shen W, et al. insulin-like growth factor binding protein 2 enhances glioblastoma invasion by activating invasionenhancing genes. Cancer Res. 2003; 63:4315-4321. (Pubitemid 36950996)
21. Lamszus K, Kunkel P, Westphal M. Invasion as limitation to anti-angiogenic glioma therapy. Acta Neurochir Suppl. 2003; 88: 169-177.
22. Du R, Lu KV, Petritsch C, et al. HIF1 α induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell. 2008; 13:206-220. (Pubitemid 351318372)
23. Rubenstein JL, Kim J, Ozawa T, et al. Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia. 2000; 2:306-314.
24. di Tomaso E, Frosch MP, Auluck PK, et al. Characterization of blood vessels in brain autopsies of GBM patients who received antiangiogenic treatment [abstract]. J Clin Oncol. 2008;26:abstract 2009.
25. Sakariassen PO, Prestegarden L, Wang J, et al. Angiogenesis-independent tumor growth mediated by stem-like cancer cells. Proc Natl Acad Sci USA. 2006; 103:16466-16471.
26. Park CM, Park MJ, Kwak HJ, et al. Ionizing radiation enhances matrix metalloproteinase-2 secretion and invasion of glioma cells through Src/epidermal growth factor receptor-mediated pp38/Akt and phosphatidylinositol 3-kinase/Akt signaling pathways. Cancer Res. 2006; 66:8511-8519.
27. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med. 2001; 7:987-989.
28. Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell. 2005; 8:299-309. (Pubitemid 41443415)
29. Zhou Q, Guo P, Gallo JM. Impact of angiogenesis inhibition by sunitinib on tumor distribution of temozolomide. Clin Cancer Res. 2008; 14:1540-1549. (Pubitemid 351413939)
30. Ma J, Pulfer S, Li S, Chu J, Reed K, Gallo JM. Pharmacodynamicmediated reduction of temozolomide tumor concentrations by the angiogenesis inhibitor TNP-470. Cancer Res. 2001; 61:5491-5498. (Pubitemid 32694932)
31. Dong J, Grunstein J, Tejada M, et al. VEGF-null cells require PDGFR α signaling-mediated stromal fibroblast recruitment for tumorigenesis. Embo J. 2004; 23:2800-2810. (Pubitemid 39013552)
32. Willett CG, Boucher Y, Duda DG, et al. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol. 2005; 23:8136-8139. (Pubitemid 46657433)
33. Fischer H, Taylor N, Allerstorfer S, et al. Fibroblast growth factor receptor-mediated signals contribute to the malignant phenotype of non-small cell lung cancer cells: therapeutic implications and synergism with epidermal growth factor receptor inhibition. Mol Cancer Ther. 2008; 7:3408-3419.